# Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE)

> **NCT04704713** · PHASE3 · COMPLETED · sponsor: **Clinuvel Pharmaceuticals Limited** · enrollment: 31 (actual)

## Conditions studied

- Polymorphic Light Eruption

## Interventions

- **DRUG:** Afamelanotide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04704713
- **Lead sponsor:** Clinuvel Pharmaceuticals Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05-05
- **Primary completion:** 2010-12-09
- **Final completion:** —
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2021-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04704713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04704713, "Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04704713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*